DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "NGS-based RNA-seq Market by Products & Services (Sample Preparation, Consumables, Bioinformatics), Technology, Application (De novo, Transcriptome Epigenetics, Small RNA), End User (Research Centers, BioPharma Companies) - Global Forecast to 2022" report to their offering.
The global NGS-based RNA-seq market is projected to reach USD 2.65 Billion by 2022 from USD 1.05 Billion in 2017, at a CAGR of 20.2% during the forecast period.
Factors such as the advantages of RNA-seq over microarray technology, technological advancements in RNA-seq products, increasing number of RNA-seq grants, increasing number of research activities, and rapid growth in precision medicine are driving the growth of the NGS-based RNA-seq market. On the other hand, accuracy and standardization concerns in diagnostic testing and the lack of skilled technical personnel are some of the key factors limiting the growth of the market.
In 2016, the sequencing platforms and consumables segment is expected to account for the largest share of the market. The data analysis, storage, and management is expected to register the highest growth rate owing to its development of more efficient data analysis solutions and growing computational capabilities of data analytics providers.
Research centers and academic & government institutes segment accounted for the largest share of the global market in 2016 due to the increasing focus of market players on providing efficient RNA-seq products & services for research applications and the growing number of government funding programs.
However, the hospitals and clinics segment is expected to register the highest growth due to the growing number of agreements between companies and hospitals for the development of advanced tests and products catering to the specific needs of hospitals and clinics. Based on applications, the market is categorized into four segments, namely, de novo transcriptome assembly, expression profiling analysis, variant calling & transcriptome epigenetics, and small RNA sequencing.
The expression profiling analysis segment accounted for the major share of the global NGS-based RNA-seq market owing to the technological advantages of expression profiling applications.
Key Topics Covered:
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Global NGS-Based RNA Sequencing Market, By Product & Service
7 Global NGS-Based RNA Sequencing Market, By Technology
8 Global NGS-Based RNA Sequencing Market, By Application
9 Global NGS-Based RNA Sequencing Market, By End User
10 Global NGS-Based RNA Sequencing Market, By Region
11 Competitive Landscape
12 Company Profiles
- 10X Genomics, Inc. (U.S.)
- Agilent Technologies (U.S.)
- Bgi (China)
- Biomatters Ltd. (New Zealand)
- Bio-Rad Laboratories, Inc. (U.S.)
- Cofactor Genomics, Inc. (U.S.)
- Eurofins Scientific (Luxembourg)
- F. Hoffmann-La Roche Ag (Switzerland)
- Gatc Biotech Ag (Germany)
- Genewiz, Inc. (U.S.)
- Hamilton Company (U.S.)
- Illumina, Inc. (U.S.)
- Intrexon Corp. (U.S.)
- Macrogen, Inc. (South Korea)
- Medgenome Inc. (U.S.)
- Novogene Corporation (China)
- Nugen Technologies Inc. (U.S.)
- Otogenetics Corporation (U.S.)
- Oxford Nanopore Technologies (U.K.)
- Pacific Biosciences of California, Inc. (U.S.)
- Perkinelmer, Inc. , (U.S.)
- Personalis Inc. (U.S.)
- Qaigen N.V. (Germany)
- Takara Holdings Inc. (Japan)
Thermo Fisher Scientific (U.S)
For more information about this report visit https://www.researchandmarkets.com/research/8g4dkl/ngsbased_rnaseq